13:00- |
개회사 (대한약학회 회장) |
PL |
좌장: 김수열 (NCC), 차신우 (KIT) |
14:00-14:30 |
전영호 고려대 |
Discovery of small molecule cytokine inhibitors using fragment-based platform |
14:30-15:00 |
김영우 NCC |
항암 신약 개발에서 국립암센터의 역할 |
15:00-15:30 |
권병목 KRIBB |
Targeting Arp2/3 complex for development of anti-metastatic agents |
15:30-16:00 |
오구택 이화여대 |
Anti-inflammatory therapy as a treatment of cardio-cerebrovascular disease |
S1 신약개발 Ⅰ |
좌장: 노민수 (서울대), 변영주 (고려대) |
16:30-17:00 |
김남중 경희대 |
Discovery of PRX-202 as a novel HBV entry blocker: from privileged library screening to IND enabling study |
17:00-17:30 |
장재봉 고려대 |
Single and dual targeting of mutant EGFR in non-small cell lung cancer |
17:30-18:00 |
차혁진 서울대 |
Partial reprogramming promotes repair of radiation damage in intestine |
18:00-18:30 |
김완태 충남대 |
Hippo signaling in organ size control, homeostasis, and cancer
|
18:30 |
기념촬영/저녁 식사 |
S1 신약개발 Ⅱ |
좌장: 육종인 (연세대), 김용철 (GIST) |
20:00-20:30 |
김종헌 NCC |
Targeting OncomiR Signaling for Cancer Therapeutics |
20:30-21:00 |
이선재 GIST |
Systems medicine of human microbiome and metabolism |
21:00-21:30 |
박지환 GIST |
Single cell analysis for biomedical sciences and drug discovery |
21:30-22:00 |
육종인 연세대 |
Effectiveness of Pro-drug BMP-7 for skin fibrosis |